Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| FABm022-01 | Mouse | PE-Labeled Monoclonal Anti-Human CD69 Antibody, Mouse IgG1 (3C5B7) (0.03% Proclin) |
|
||
| CD9-H5222 | Human | Human CD69 / CLEC2C Protein, His Tag |  |
|
Flow cytometric analysis of Jurkat staining with PE-Labeled Monoclonal Anti-Human CD69 Antibody, Mouse IgG1 (3C5B7) (Cat. No. FABm022-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Decitabine/Cedazuridine | ASTX-727-LD; ASTX-727-10; E-7727/decitabine; Decitabine/E7727; ASTX-727 | Approved | Astex Pharmaceuticals Inc, National Cancer Institute | INAQOVI, Inaqovi, Inqovi | United States | Myelodysplastic Syndromes | Otsuka Pharmaceutical Co Ltd | 2020-07-07 | Leukemia, Myelogenous, Chronic; Leukemia; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Triple Negative Breast Neoplasms; Neoplasms; Mesothelioma; Pancytopenia; Leukemia, Myeloid, Acute; Glioma; Cytopenia; Metastatic breast cancer; Nervous System Neoplasms | Details |
| Mecobalamin | E-0302 | Approved | Methycobal, Naso B12, Myelogen, 悦敏兴, 弥尔神, 弥可保, 曲力, 奇信, ROZEALAMIN, NASOCOBAL, RHINOCOBAL | Peripheral Nervous System Diseases; Autistic Disorder; Neuritis; Neuralgia; Vitamin B 12 Deficiency; Amyotrophic Lateral Sclerosis; Fibromyalgia | Details | |||||
| Azacitidine | NSC-102816; 5-aza-CR; CC-486; NS-17; U-18496; NEX-18; NEX-18a | Approved | Celgene Corp | 维达莎, Vidaza, Onureg | United States | Myelodysplastic Syndromes | Bristol-Myers Squibb Company | 2004-05-19 | Leukemia, Myelomonocytic, Juvenile; Contracture; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Breast Neoplasms; Prostatic Neoplasms; Tuberculosis, Pulmonary; Brain Neoplasms; Sarcoma; Osteosarcoma; Hepatic Insufficiency; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Multiple Myeloma; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Lung Neoplasms; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Leukemia, Large Granular Lymphocytic; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Cerebral Palsy; Nasopharyngeal Neoplasms; Intestinal Neoplasms; Ependymoma; Leukemia, Myeloid; Lymphoma, T-Cell, Peripheral; Head and Neck Neoplasms; Solid tumours; Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Plasmacytoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; beta-Thalassemia; Hodgkin Disease; Glioblast | Details |
| Triclabendazole | EGA-230B; CGA-89317; NVP-EGA230 | Approved | Novartis Pharma Ag | Egaten, Fasinex, Triclathera | Iran | Fascioliasis | Novartis Pharma Ag | 1989-01-01 | Fascioliasis | Details |
| Decitabine | 5-aza-CdR; NSC-127716; AzadC; E-7373; DAC | Approved | Eisai Co Ltd | Dacogen, 达珂 | Mainland China | Myelodysplastic Syndromes | Mgi Pharma Inc | 2006-05-02 | Burkitt Lymphoma; Multiple Myeloma; Cycloplegia; Lymphoma, Mantle-Cell; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Neuroblastoma; Vulvar Neoplasms; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Colorectal Neoplasms; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Adenocarcinoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Lung Neoplasms; Anemia, Sickle Cell; Myelodysplastic-Myeloproliferative Diseases; Precancerous Conditions; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms, Male; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Melanoma; Thyroid Cancer, Papillary; Esophageal Neoplasms; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Accelerated Phase; Leukemia; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Purpura, Thrombocytopenic, Idiopathic; Liver Neoplasms; Erectile Dysfunction; Hypotension; Anaphylaxis; Thalassemia; Leukemia, Myelogenous, Chronic; Neutropenia; Myelodysplastic Syndromes; L | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Curcumin | VOLT-03; VOLT-3; NSC-32982 | Phase 3 Clinical | University Of Pennsylvania | Neuralgia; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Adenocarcinoma, Mucinous; Cigarette Smoking; Cervical Intraepithelial Neoplasia; Cognitive Dysfunction; Uterine Cervical Dysplasia; Asthma; Osteoarthritis; Primary Myelofibrosis; Colorectal Neoplasms; Dentist-Patient Relations; Periapical Diseases; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tobacco Use Disorder; Oral Submucous Fibrosis; Thrombocythemia, Essential; Cognition Disorders; Uterine Cervical Neoplasms; Stomatitis; Neoplasm Metastasis; Macular Degeneration; Condylomata Acuminata; Carcinoma, Non-Small-Cell Lung; Aortic Aneurysm, Abdominal; Pancytopenia; Adenocarcinoma; Crohn Disease; Diabetes Mellitus; Hypogonadism; Renal Insufficiency, Chronic; Periodontitis; Lichen Planus, Oral; Diabetes Mellitus, Type 2; Neoplasms; Stomach Neoplasms; Spasm; Digestive System Diseases; Pain; Radiodermatitis; Gastritis, Atrophic; Depression; Myelodysplastic Syndromes; Metabolic Dysfunction-Associated Steatotic Liver Disease; Polycythemia | Details |
| Azacitidine/Cedazuridine | ASTX-030 | Phase 3 Clinical | Otsuka Pharmaceutical Co Ltd | Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Guadecitabine Sodium | SGI-110; S-110; 0RB89YH367 (UNII code) | Phase 3 Clinical | Otsuka Holdings Co Ltd | Klatskin Tumor; Carcinoma, Hepatocellular; Adenocarcinoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Myeloproliferative Disorders; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Stomach Neoplasms; Pheochromocytoma; Carcinoma, Renal Cell; Chondrosarcoma; Kidney Neoplasms | Details |
| EF-009 | EF-009 | Phase 2 Clinical | Everfront Biotech Co Ltd | Pancreatic Neoplasms | Details |
| NTX-301 | NTX-303 | Phase 2 Clinical | Southern Research Institute, Pinotbio Inc | Solid tumours; Ovarian Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Carcinoma, Transitional Cell; Leukemia, Myeloid, Acute; Glioma | Details |
| FdCyd | NSC-48006; Ro-5-1090 | Phase 2 Clinical | City Of Hope National Medical Center, National Cancer Institute | Head and Neck Neoplasms; Esophageal Neoplasms; Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Azacitidine (Boryung Pharmaceutical) | Phase 2 Clinical | Boryung Pharmaceutical Co Ltd | Neoplasms | Details | |
| Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk) | EPI-01; EPI01; NN 7533 | Phase 2 Clinical | Epicdestiny | Anemia, Sickle Cell | Details |
| GSK4172239D | GSK-4172239-D | Phase 1 Clinical | Glaxosmithkline Plc | Hematologic Diseases; Anemia, Sickle Cell | Details |
This web search service is supported by Google Inc.
A-Z
